Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Theralase Technologies Inc.
  6. News
  7. Summary
    TLT   CA88337V1004

THERALASE TECHNOLOGIES INC.

(TLT)
  Report
Delayed Bourse de Toronto  -  03:32 2022-09-23 pm EDT
0.2650 CAD   +6.00%
09/23Theralase Technologies Closes $2.5 Million Private Placement Equity Financing
MT
09/22Theralase® Closes $2.5M Private Placement Equity Financing
AQ
09/22Theralase Technologies Inc. announced that it has received CAD 2.5 million in funding
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Theralase® Closes $2.5M Private Placement Equity Financing

09/22/2022 | 05:56pm EDT

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a non-brokered private placement offering (“Offering”) of units (“Units”). On closing, the Corporation issued an aggregate of 10,000,000 Units at a price of $0.25 per Unit for aggregate gross proceeds of approximately $2,500,000.

Each Unit consisted of one common share of the Company (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $0.35 per share for a period of 24 months following the date of issuance.

In connection with the Offering, the Company paid a finder’s fee of $10,167 in cash and 76,800 in Common Shares at a price of $0.25 per Common Share and issued 58,734 finder’s warrants. Each finder’s warrant is exercisable into one Common Share at an exercise price of $0.35 per share for a period of 24 months after the closing of the Offering.

The Company intends to use the proceeds of the Offering for the following:

  • Good Laboratory Practice (“GLP”) Toxicology Study for Intravenous installation of Rutherrin intended for the treatment of Non Small Lung Cancer (“NSCLC”) and Glio Blastoma Multiforme (“GBM”)
  • Advancement of Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study
  • Working capital and general corporate purposes

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful, including the United States.

All securities issued under the Offering will be subject to a four month and one day hold period from the closing date under applicable Canadian securities laws, which expires on January 22, 2023. The Offering is subject to receipt of final acceptance from the TSX Venture Exchange.

Related Party Transactions
An aggregate of 2,400,000 Units, representing gross proceeds of $600,000, were issued to certain insiders of the Corporation. Pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and TSX Venture Exchange Policy 5.9, such insider subscriptions are a “related party transaction.” The Corporation is exempt from the formal valuation requirement of MI 61-101 in connection with the insider subscriptions in reliance on section 5.5(b) of MI 61-101, as no securities of the Corporation are listed or quoted for trading on the Toronto Stock Exchange, the New York Stock Exchange, the American Stock Exchange, the NASDAQ stock market or any other stock exchange outside of Canada and the United States. Additionally, the Corporation is exempt from obtaining minority shareholder approval in connection with the insider subscriptions in reliance on section 5.7(1)(a) of MI 61-101 as the aggregate value of the insider subscriptions does not exceed 25% of the market capitalization of the Corporation. Due to the limited time between the launch and the close of the Offering, there will be less than 21 days between the date the Corporation files its material change report in respect of the Offering and the completion date of the Offering.

About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedar.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions including statements related to the current expectations of Company's management for future research, development and commercialization of the Company’s Photo Dynamic Compounds and their drug formulations, including preclinical research, clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to: adequately fund and secure the requisite regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion to implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company’s operations may not be available or may not be available on terms that are commercially favorable to the Company, the risk that the Company’s drug formulations may not be effective against the conditions tested in its clinical studies, the risk that the Company’s fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these forward- looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will successfully come to fruition, as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.

Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer
khachey@theralase.com
416.699.LASE (5273) x 224


Primary Logo

Source: Theralase Technologies Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about THERALASE TECHNOLOGIES INC.
09/23Theralase Technologies Closes $2.5 Million Private Placement Equity Financing
MT
09/22Theralase® Closes $2.5M Private Placement Equity Financing
AQ
09/22Theralase Technologies Inc. announced that it has received CAD 2.5 million in funding
CI
08/30THERALASE TECHNOLOGIES : Release's Q222 Interim Financial Statements
PU
08/30THERALASE TECHNOLOGIES : Interim Q222 Managment Discussion & Analaysis
PU
08/29Theralase Releases Q222 Interim Financial Statements
AQ
08/29Theralase Technologies Inc. Reports Earnings Results for the Second Quarter and Six Mon..
CI
06/28THERALASE TECHNOLOGIES : Expands Intellectual Property Portfolio
PU
06/28Theralase Edging Up As Expands Intellectual Property Portfolio
MT
06/28Theralase Expands Intellectual Property Portfolio
AQ
More news
Financials
Sales 2022 1,09 M 0,80 M 0,80 M
Net income 2022 -6,41 M -4,72 M -4,72 M
Net Debt 2022 - - -
P/E ratio 2022 -8,83x
Yield 2022 -
Capitalization 57,1 M 42,1 M 42,1 M
Capi. / Sales 2022 52,4x
Capi. / Sales 2023 51,9x
Nbr of Employees 20
Free-Float 97,3%
Chart THERALASE TECHNOLOGIES INC.
Duration : Period :
Theralase Technologies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,27 CAD
Average target price 1,20 CAD
Spread / Average Target 353%
EPS Revisions
Managers and Directors
Arkady Mandel Director, Chief Executive & Scientific Officer
Kristina Hachey Chief Financial Officer & Director
Matthew Perraton Chairman
Randy Bruder Independent Director
Guy J. Anderson Independent Director
Sector and Competitors